PHENOMENOLOGY OF MAJOR DEPRESSION

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 研究表明，下丘脑-垂体-肾上腺（HPA）轴失调影响与特定症状组相关的抑郁症的表现。 更好地理解这些差异背后的机制可能会导致抑郁症治疗的新靶点，并有助于解释先前研究中的差异，这些研究通常包括具有不同抑郁症状的受试者。 本研究旨在评估健康志愿者和抑郁症患者的HPA活性和急性应激反应的措施，因为它们与特定的症状组有关。 假设是抑郁症中HPA轴活性升高与失眠，食欲不振/体重减轻和焦虑有关，而低HPA活性与疲劳，食欲增加/体重增加和缺乏能量有关。 此外，假设HPA活性增加、失眠症状、食欲不振/体重减轻和焦虑与对压力的更大反应相关，而假设低HPA活性和疲劳症状、食欲增加/体重增加和缺乏能量与对压力的反应降低相关。 这些假设将通过在三种不同的条件下收集血液，尿液和唾液中的应激激素进行测试;基线，使用两种FDA批准的药物进行诊断测试后，以及对社会压力测试的反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Studies suggest that hypothalamic-pituitary-adrenal (HPA) axis dysregulation influences the presentation of depression related to specific groups of symptoms. A better understanding of the mechanisms underlying these differences could lead to novel targets for the treatment of depression, and help to explain variability among previous studies that typically included subjects with varying symptoms of depression. This study is designed to assess HPA activity and measures of acute stress responses in healthy volunteers and depressed patients as they relate to specific groups of symptoms. The hypothesis is that elevated HPA axis activity in depression is associated with insomnia, loss of appetite/weight loss, and anxiety, whereas low HPA activity is linked with fatigue, increased appetite/weight gain and lack of energy. Moreover, increased HPA activity, symptoms of insomnia, loss of appetite/weight loss and anxiety are hypothesized to correlate with a greater response to stress, whereas low HPA activity and symptoms of fatigue, increased appetite/weight gain and lack of energy are hypothesized to correlate with a decreased response to stress. These hypotheses will be tested by collection of stress hormones in the blood, urine and saliva during three separate conditions; baseline, following a diagnostic test using two FDA approved medications, and in response to a social stress test.